- Schrödinger Inc SDGR posted Q3 sales of $29.9 million, +16% Y/Y, missing the consensus of $31.58 million.
- Software revenue was $24.3 million, +6% primarily due to increased sales from existing customers and the addition of new customers, partially offset by multi-year contracts executed in Q3 FY20.
- Drug discovery revenue was $5.6 million, compared to $2.9 million a year ago, and it included the recognition of $4.4 million of revenue from the collaboration with Bristol Myers Squibb & Co BMY.
- Software gross margin was 73%, down from 81% a year ago, reflecting planned investments and increased royalty expenses in the quarter.
- Operating expenses increased to $45.8 million, compared to $30.7 million in Q3 FY20.
- Schrödinger posted a Q3 EPS loss of $(0.49), missing the consensus of $(0.43) and a turnaround from the income of $0.06.
- The company held cash and equivalents of $600.2 million.
- Guidance: Schrödinger revised the upper end of FY21 sales guidance and forecasts revenue of $124 million - $134 million, compared to earlier guidance of $124 million - $142 million, below the consensus of $138.49 million.
- The company is maintaining its full-year software revenue expectation of $102 million - $110 million.
- It lowered its full-year drug discovery revenue expectation to $22 million - $24 million, from the earlier expectation of $22 million - $32 million, primarily due to the timing of anticipated milestones from collaborators.
- Price Action: SDGR shares are down 15.4% at $43.29 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
